Targeting dendritic cells with antigen-containing liposomes: A highly effective procedure for induction of antitumor immunity and for tumor immunotherapy

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4357-4365

  Van Broekhoven, Christina L ^a   Parish, Christopher R ^b   Demangel, Caroline ^c   Britton, Warwick J ^d   Altin, Joseph G ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Biology and Environment   (Australia)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (NITRILOTRIACETIC ACID) DITETRADECYLAMINE; ACETIC ACID DERIVATIVE; CANCER VACCINE; CHEMOKINE; EOTAXIN; GAMMA INTERFERON; HEXAHISTIDINE; HISTIDINE DERIVATIVE; LIPID; LIPOPOLYSACCHARIDE; LIPOSOME; METAL CHELATE; OVALBUMIN; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; EOSINOPHIL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOTHERAPY; MALE; MELANOMA CELL; MEMBRANE VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SPLEEN LYMPHOCYTE; TUMOR IMMUNITY;

AMINES; ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; FEMALE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; LIPOSOMES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NITRILOTRIACETIC ACID; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 3042523520     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0138     Document Type: Article

References (44)

1. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-73.
2. Heiser A, Maurice MA, Yancey DR, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2000;166:2953-60.
3. Gatza E, Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 2002;169:5227-35.
4. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
5. Marten A, Renoth S, Schmidt-Wolf IG. Increase of the stimulatory effect of dendritic cells by pulsing with apoptotic bodies transfected with the MHC class II gene. Mol Immunol 2002;39:395-8.
6. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990;172:631-40.
7. Wilson HL, Ni K, O'Neill HC. Identification of progenitor cells in long-term spleen stromal cultures that produce immature dendritic cells. Proc Natl Sci USA 2000;9: 4784-9.
8. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993;178:509-19.
9. Loike JD, Sodeik B, Cao L, et al. CD11c/CD18 on neutrophils recognizes a domain at the N-terminus of the A alpha chain of fibrinogen. Proc Natl Acad Sci USA 1991;88:1044-8.
10. Bilsland CA, Diamond MS, Springer TA. The leukocyte integrin p150,95 (CD11c/CD18) as a receptor for iC3b: activation by a heterologous beta subunit and localization of a ligand recognition site to the I domain. J Immunol 1994;152:4582-9.
11. Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelium cells is involved in antigen processing. Nature 1995;375:151-5.
12. Mahnke K, Guo M, Lee S, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000;151:673-84.
13. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67.
14. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-79.
15. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on Major Histocompatibility Complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002;196:1627-38.
16. Ignatius R. Mahnke K, Rivera M, et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8+ T-cell responses in vivo. Blood 2000;96:3505-13.
17. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 2003;63:2526-34.
18. Chikh G, Schutze-Redelmeier M-P. Liposomal delivery of CTL epitopes to dendritic cells. Bioscience Reports 2002;22:339-53.
19. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995;1239:133-44.
20. Lopez de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to humn B-cell lymphoma Cancer Res 1998;58:3320-30.
21. Copland MJ, Baird MA, Rades T, et al. Liposomal delivery of antigen to human dendritic cells Vaccine 2003;21:883-90.
22. Fukasawa M, Shimizu Y, Shikata K, et al. Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ CTLs. FEBS Lett 1998;441:353-6.
23. Serre K, Shimizu Y, Shikata K, et al. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J Immunol 1998;161:6059-67.
24. Altin JG, White FAJ, Easton CJ. Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with IAsys biosensor to study receptor-ligand interactions on model membranes. Biochim Biophys Acta 2001;1513:131-48.
25. Inaba K, Swiggard WJ, Inaba M, et al. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLC-145: I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 1995;163:148-56.
26. Metlay JP, Witmer-Pack MD, Agger R, Crowley MT, Lawless D, Steinman RM. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal-antibodies. J Exp Med 1990;171:1753-71.
27. van Broekhoven CL, Altin JG. A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol Cell Biol 2001;79:274-84.
28. O'Neill HC, Jonas N, Wilson H, Ni K. Immunotherapeutic potential of dendritic cells generated in long-term stroma-dependent cultures, Cancer Biother. Radiopharm 1999; 14:263-76.
29. Greenfield EA, Howard E, Paradis T, et al. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding. J Immunol 1997; 158:2025-34.
30. Maeda T, Balakrishnan K, Mehdi SQ. A simple and rapid method for the preparation of plasma membranes. Biochim Biophys Acta 1983;731:115-20.
31. van Broekhoven CL, Altin JG. A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy. Internal J Cancer 2002;98:63-72.
32. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
33. Papahadjopoulos D, Allen TM, Gabizon A. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci 1991;88:11460-4.
34. van Broekhoven CL, Parish CR, Vassiliou G, Altin JG. Engrafting costimulator molecules onto tumor cell surfaces with chelator lipids: a potentially convenient approach in cancer vaccine development. J Immunol 2000;164:2433-43.
35. Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197:387-93.
36. Matzinger P. An innate sense of danger. Sem Immunol 1998;10:399-415.
37. Petrov AB, Kolenko VM, Koshkina NV, et al. Non-specific modulation of the immune response with liposomal menigococcal lipopolysaccharide: role of different cells and cytokines. Vaccine 1994;12:1064-70.
38. van Slooten ML, Berman O, Romoren K, Kedar E, Crommelin DJ, Storm G. Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. Biochim Biophys Acta 2001;1530:134-45.
39. Hockertz S, Franke G, Kniep E, Lohmann-Matthes ML. Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo. J Interferon Res 1989;9:591-602.
40. Kedar E, Pagli O, Golod G, Babal I, Barenholz Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-α show improved pharmacokinetics and biological acivity and reduced toxicity in mice J Immunother 1997;20:180-93.
41. Lutz MB, Assmann CU, Girolomoni G, Ricciardi-Castagnoli P. Different cytokines regulate antigen uptake and presentation of a precursor dendritic cell line. Eur J Immunol 1996;26:586-94.
42. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatability complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
43. Chang CH, Furue M, Tamaki K. Selective regulation of ICAM-1 and MHC complex class I and II molecule expression on epidermal langerhans cells by some of the cytokines released by keratinocytes and T cells. Eur J Immunol 1994;24:2889-95.
44. Escourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. Prime-boost immunization generates a high frequency, high avidity (CD8+) cytotoxic T lymphocyte population. Int Immunol 2002;14:31-7.